AVLN (Avalyn Pharma) 12-1 Month Momentum %: N/A% (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVLN Avalyn Pharma Inc AVLN
12 GF Score
Price $31.35
View Full Analysis

What is Avalyn Pharma 12-1 Month Momentum %?

Avalyn Pharma AVLN -5.63% 12 12-1 Month Momentum % is N/A% as of Sep. 21, 2026. GuruFocus rates AVLN with a GF Score™ of 12/100. Among 1,352 Biotechnology companies, Avalyn Pharma ranks worse than 73964.42% on this metric.

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-21), Avalyn Pharma's 12-1 Month Momentum % is N/A%.

The industry rank for Avalyn Pharma's 12-1 Month Momentum % or its related term are showing as below:

AVLN's 12-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -20.52
* Ranked among companies with meaningful 12-1 Month Momentum % only.

Avalyn Pharma  (NAS:AVLN) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Avalyn Pharma 12-1 Month Momentum % Related Terms

AVLN
12GF Score
Avalyn Pharma Inc AVLN
12-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalyn Pharma  (NAS:AVLN) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 12-1 Month Momentum % →
What does a 12-1 Month Momentum % of N/A% mean?
Avalyn Pharma (AVLN) has a 12-1 Month Momentum % of N/A% as of Sep. 21, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Avalyn Pharma and its competitors. According to the industry distribution chart, Avalyn Pharma ranks #999999 out of 1352 companies in the Biotechnology industry.
Is Avalyn Pharma's 12-1 Month Momentum % too high?
Avalyn Pharma's current 12-1 Month Momentum % is N/A%. Based on the distribution chart, Avalyn Pharma ranks #999999 out of 1352 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Avalyn Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Avalyn Pharma's 12-1 Month Momentum % compare to LBRX and LTGO?
According to the Biotechnology industry distribution chart, Avalyn Pharma ranks #999999 out of 1352 companies for 12-1 Month Momentum %. This places Avalyn Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Avalyn Pharma and its competitors. Avalyn Pharma's current 12-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalyn Pharma stock overvalued right now?
Avalyn Pharma (AVLN) has a current 12-1 Month Momentum % of N/A%. The current 12-1 Month Momentum % is N/A%. Avalyn Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Avalyn Pharma (AVLN), the current 12-1 Month Momentum % is N/A% as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avalyn Pharma Business Description

Address 105 W First Street, Boston, MA, USA, 02127
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
12GF Score

Get the complete analysis for AVLN

12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.35
Price